Crenezumab misses endpoints in mid stage trial for Alzheimers Disease - Genentech/Roche

Data presented by Genentech/Roche at the Alzheimers Association International Conference in Copenhagen showed that intravenous infusion crenezumab did not meet its primary endpoints for cognition and function in a 500 person study. A positive finding ("a hint of a benefit") was made in a sub group of mild Alzheimers patients. Crenezumab is an anti amyloid beta antibody.Genentech/Roche has yet to decide whether to progress to phase III trials.